In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
about
Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicityTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensBaseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001In vivo pharmacodynamic activity of daptomycinAssessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelLY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci.In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteriaDaptomycin (LY146032) treatment of experimental enterococcal endocarditisActivities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendationsComparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalisEx vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycinAntimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studiesActivity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strainsOritavancin--an investigational glycopeptide antibiotic.Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci.Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity dataFailure of routine susceptibility tests to detect imipenem resistance among strains of methicillin-resistant Staphylococcus aureus.Effect of protein binding of daptomycin on MIC and antibacterial activity.Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.Therapeutic update on glycopeptide and lipopeptide antibiotics.In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptideComparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model.In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteriaPharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.Enterococcus, an emerging pathogen.Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.Effect of divalent cations on the structure of the antibiotic daptomycin.Daptomycin: a novel agent for Gram-positive infections.Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
P2860
Q28343011-D5EF3C71-1244-4E28-A1FB-FC6BC7DB75A7Q33788308-4EF3FBC6-533B-4342-B183-ADD28402635FQ34939045-64F5C038-F386-44E5-AB63-6B5C3CDAD040Q35005549-1B15DD40-E800-46B4-9D6E-1CCD105E41F5Q35276965-36ECB43E-04A0-48B0-AA56-219076575939Q35289979-7AF6C2B5-E4BA-4A28-ADC3-BC821FBA25DEQ35307059-EB9AE7DF-D412-42F5-89E8-7F001A0252D0Q35309352-33CE8BAF-5E5F-4F8F-B481-BFAE29179B1EQ35329160-A2675D16-E7D0-45F6-ADC2-A97B90A27824Q35332478-44AC03CD-6B3B-4017-8407-2C1109118737Q35350299-EC2623DA-B219-4F09-983A-4320178940A9Q35355587-D7771D2F-3E82-46DE-94B7-71A9CC4CC1A0Q35539120-981585FA-B251-40C1-86F6-372E925D3871Q35540772-3150EE0B-0394-4A1A-B36F-F02CE4FE6EE6Q35541070-81AD5D5D-EBB3-46A1-A76D-CF60CC1BAD72Q35543452-2C1427B9-FF11-4EE9-8165-1873EC59B463Q36426011-2A34D480-066C-472E-9297-E6187F94010EQ36505466-8BB0BD1D-E768-466A-9064-CE31D0CA0B44Q36751113-CF17D414-0CDD-45D4-9A70-0AE9708F4E39Q36754338-4ADF3570-1713-4F01-9A35-B26E26791B53Q36757414-B43B53CA-57AF-460F-9F2E-C6C224C0B8E5Q36757990-9B9948D1-E2F7-4640-B678-3CB438C5AB4BQ39291062-48F38D86-F59B-4FBA-9054-47CE5C0C1884Q39817448-1525449C-53F9-4ED0-B58C-99665781861FQ39817484-EA80D22D-8D75-4CE6-BE0D-94CD6CDA52B0Q39817510-0A600E4C-6583-4537-88E7-D9E959C4F0B3Q39817718-E4999A35-6726-4367-8B11-696A9A5AB827Q40087244-B7A9049B-C2DE-4FEC-B41E-45E899E8E068Q40785841-39352954-DC65-4AA7-A663-C78648629E75Q44672108-3230128C-32D3-47CA-8E9E-569778813C86Q46925250-3E808FCD-8E0C-448A-AF52-E855A49F0371Q53852746-668BB4CF-D91C-4093-B8EB-E97B4891C7B3Q54412807-44E35988-E436-4EE5-8B2D-61795C68F84C
P2860
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@ast
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@en
type
label
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@ast
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@en
prefLabel
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@ast
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@en
P2860
P356
P1476
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci
@en
P2093
P2860
P304
P356
10.1128/AAC.30.5.781
P407
P577
1986-11-01T00:00:00Z